Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders
Open accessThe DOI matches its Crossref record; 135 of the 137 references it cites were found in a registry or an index.
Abstract
Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Between 20% and 60% of patients with IBS have enhanced visceral perception to various physiological stimuli (eg, mechanical or electrical).41”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [41]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444 · cited 1×
“…in this enormous depository of bacteria might influence the development of the gut, its susceptibility to stress (see Shanahan and Kiely [2007] and references therein) and major disorders such as obesity [Turnbaugh et al. 2006], inflammatory bowel [Frank et al. 2007] and IBS [Kassinen et al. 2007].”
BackgroundLongstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Self-citationFrank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611 · cited 1×
“…in this enormous depository of bacteria might influence the development of the gut, its susceptibility to stress (see Shanahan and Kiely [2007] and references therein) and major disorders such as obesity [Turnbaugh et al. 2006], inflammatory bowel [Frank et al. 2007] and IBS [Kassinen et al. 2007].”
BackgroundAnda, R. F., Felitti, V. J., Bremner, J. D., Walker, J. D., Whitfield, C., Perry, B. D., Dube, S. R., & Giles, W. H. (2006) · European archives of psychiatry and clinical neuroscience · doi:10.1007/s00406-005-0624-4 · Cited by 4,292
Effect of In Utero and Early-Life Conditions on Adult Health and Disease
Gluckman, P. D., Hanson, M. A., Cooper, C., & Thornburg, K. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708473 · Cited by 3,898 · cited 3×
“cardiovascular, metabolic and osteoporosis [Gluckman et al. 2008].”
BackgroundInfluentialEpigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse
McGowan, P. O., Sasaki, A., D'Alessio, A. C., Dymov, S., Labonté, B., Szyf, M., Turecki, G., & Meaney, M. J. (2009) · Nature Neuroscience · doi:10.1038/nn.2270 · Cited by 3,531 · cited 1×
“More recently McGowan and colleagues argued that these results may translate to humans by demonstrating epigenetic changes in hippocampal glucocorticoid receptors of suicide victims who suffered childhood abuse [McGowan et al. 2009].”
BackgroundU.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Combinatorial patterns of histone acetylations and methylations in the human genome
Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Peng, W., Zhang, M. Q., et al. (2008) · Nature Genetics · doi:10.1038/ng.154 · Cited by 2,331 · cited 1×
“For example, Wang and coworkers showed 17 histone modifications in CD4þ T cells, which affected 3286 promoters [Wang et al. 2008].”
BackgroundThe burden of selected digestive diseases in the United States
Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., & Rubin, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32978 · Cited by 1,512 · cited 2×
“…benefit for FGID treatments Although IBS has been shown to be associated with a significant healthcare and economic burden [Longstreth et al. 2006; Sandler et al. 2002], relatively little risk is accepted by regulatory agencies and many healthcare providers despite the beneficial effects on…”
BackgroundO’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Research works printed but not linked: 12
- Camilleri, M., 2008, Am J Physiol, 295, G219
- Camilleri, M., 2008, Am J Physiol, 294, G13
- Dukes, G.E., 2009, Neurogastroenterol Motil, 21, 84
- Kelleher, D.L., 2008, Neurogastroenterol Motil, 20, 131
- 10.1111/j.1572-0241.2000.01766.x · DOI · Paper page
- Mayer, E.A., 2001, Am J Physiol Liver Physiol, 280, G519
- 10.1111/j.1572-0241.1998.440_j.x · DOI · Paper page
- Niesler, B., 2009, Eur J Gastroenterol Hepatol
- O’Mahony, S.M., 2010, Neurogastroenterol Motil
- Tahara, T., 2008, Hepatogastroenterol, 55, 979
- Takai, N., 2010, J Oncol, 458431
- Waterland, R.A., 2009, Horm Res, 71, 13
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
“41 Hypersensitivity to mechanical distension of the gut is reported by more patients with IBS-D than IBS-C.”
Self-citationHong, S., Zheng, G., & Wiley, J. W. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.032 · Cited by 153
“Alterations in corticotropin releasing factor signaling, the substance P/neurokinin-1 receptor system, a disrupted intestinal epithelial barrier function, and changes in the microbiota correlate with peripheral nociceptor sensitization.(2,3) Our previous studies showed that chronic stress induces reciprocal changes in…”
Richards, J. R., Lapoint, J. M., & Putze, G. B. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1349910 · Cited by 92
Gut microbiota and intestinal immunity—A crosstalk in irritable bowel syndrome
Chen, Y., Feng, S., Li, Y., Zhang, C., Chao, G., & Zhang, S. (2024) · Immunology · doi:10.1111/imm.13749 · Cited by 42
“20% – 60% of patients with IBS reported this symptom and suggested that VHS correlates with the severity of gastrointestinal symptoms [86, 87].”
Background
Metadata
- Authors
- Sanger, G. J., Chang, L., Bountra, C., & Houghton, L. A.
- Affiliations
- Queen Mary University of London (GB)
- University of California, Los Angeles (US)
- University of Oxford (GB)
- University of Manchester (GB)
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2010-05-17
- Volume
- 3
- Issue
- 5
- Pages
- 291-305
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- PMC
- PMC3002590
- OpenAlex
- W1994281253
- Cited by
- 17
- References
- 137
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2014: 1 · 2013: 3 · 2012: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Gastroenterology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- functional gastrointestinal disorders, irritable bowel syndrome, functional dyspepsia, pharmacotherapy, drug development, drug development strategy, epigenetics, genetic research, pathophysiology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. https://app.cochat.ai/papers/10.1177/1756283x10369922
- The paper
- Sanger, G. J., Chang, L., Bountra, C., & Houghton, L. A. (2010). Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x10369922
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.